MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/pds.5726

Медицинская библиотека · Pharmacoepidemiology and drug safety · 2023

Beta-blocker use and survival after pancreatic cancer surgery: A nationwide population-based cohort study.

Kirkegård Jakob, Cronin-Fenton Deirdre, Lund Andrea, Mortensen Frank Viborg

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: We examined the association between use of beta-blockers and survival in pancreatic cancer patients after curative-intent surgery.

METHODS

Using Danish healthcare registries, we conducted a population-based cohort study of all patients undergoing curative-intent surgery for pancreatic cancer in Denmark 1997-2021. We defined beta-blocker use according to exposure before surgery as current (≤90 days), recent (91-365 days), or former (366-730 days) use, requiring at least one filled prescription. Patients were followed from the date of surgery for up to 5 years. We used Cox regression to compute hazard ratios (HRs) of deaths with 95% confidence intervals (CIs), adjusting for age, sex, year of diagnosis, cardiovascular disease, diabetes, liver disease, alcohol, and smoking. We also conducted an active comparator analysis, where we used angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers as comparators instead of nonusers.

RESULTS

We included 2592 patients, of which 16.7% were beta-blocker users. Median survival for the entire population was 24.4 months. Beta-blocker use was associated with increased mortality (adjusted HR: 1.18; 95% CI: 1.04-1.34). This was evident in current (adjusted HR: 1.19; 95% CI: 1.02-1.38) and recent (adjusted HR: 1.29; 95% CI: 1.04-1.59) but not former (adjusted HR: 0.91; 95% CI: 0.64-1.43) users. In the active comparator analysis, the association between beta-blocker exposure and mortality attenuated slightly (adjusted HR: 1.12; 95% CI: 0.93-1.35).

CONCLUSIONS

We observed an association between beta-blocker use and increased mortality in patients operated for pancreatic cancer. Findings are likely explained by confounding by indication.

Для цитирования: Kirkegård Jakob, Cronin-Fenton Deirdre, Lund Andrea, Mortensen Frank Viborg. Beta-blocker use and survival after pancreatic cancer surgery: A nationwide population-based cohort study.. Pharmacoepidemiology and drug safety. 2023. DOI: 10.1002/pds.5726.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.